Sionna Therapeutics targets cystic fibrosis with a novel NBD1 stabilization mechanism, aiming to enhance CFTR function beyond current standards. SION-719 as an add-on to Trikafta and SION-451 dual combinations both approach pivotal clinical readouts in summer 2026, offering dual strategic paths. Sionna's $289.9M cash runway extends to 2028, supporting critical proof-of-concept milestones without near-term financing risk.

seekingalpha.com - 2026-06-30 07:12:54

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 13:52:13

WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:

globenewswire.com - 2026-05-27 08:00:00

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.

globenewswire.com - 2026-05-13 08:00:00

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026 Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

globenewswire.com - 2026-05-12 07:00:00

Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026

globenewswire.com - 2026-04-27 07:00:00

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Orbimed Advisors Llc sold 47,814 shares of the company's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the sale, the director directly owned 3,482,888 shares of

defenseworld.net - 2026-04-19 05:23:10

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Peter Thompson sold 47,814 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the transaction, the director owned 3,482,888 shares in

defenseworld.net - 2026-04-19 05:23:09

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Orbimed Advisors Llc sold 226,906 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $45.34, for a total transaction of $10,287,918.04. Following the transaction, the director directly owned 3,020,119 shares in the

defenseworld.net - 2026-04-19 04:38:45

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Orbimed Advisors Llc sold 235,863 shares of the firm's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company's stock,

defenseworld.net - 2026-04-19 04:05:08

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Peter Thompson sold 226,906 shares of the company's stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04. Following the completion of the sale, the director directly owned 3,020,119 shares in the

defenseworld.net - 2026-04-19 04:05:04

Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Peter Thompson sold 235,863 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company's stock, valued at

defenseworld.net - 2026-04-19 04:05:03